COGENT BIOSCIENCES
Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, Massachusetts.
COGENT BIOSCIENCES
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cogentbio.com
Total Employee:
101+
Status:
Active
Contact:
(617) 843-5032
Email Addresses:
[email protected]
Total Funding:
432.7 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail IPv6 ReCAPTCHA GoDaddy DNS ReCAPTCHA V2 AWS Global Accelerator
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-07-06 | Kiq | Kiq acquired by Cogent Biosciences | N/A |
Investors List
Logos Capital
Logos Capital investment in Post-IPO Equity - Cogent Biosciences
Commodore Capital
Commodore Capital investment in Post-IPO Equity - Cogent Biosciences
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - Cogent Biosciences
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Equity - Cogent Biosciences
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - Cogent Biosciences
Samsara BioCapital
Samsara BioCapital investment in Post-IPO Equity - Cogent Biosciences
Atlas Venture
Atlas Venture investment in Post-IPO Equity - Cogent Biosciences
OrbiMed
OrbiMed investment in Post-IPO Equity - Cogent Biosciences
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Cogent Biosciences
BVF Partners
BVF Partners investment in Post-IPO Equity - Cogent Biosciences
Official Site Inspections
http://www.cogentbio.com Semrush global rank: 4.99 M Semrush visits lastest month: 1.69 K
- Host name: 44.255.196.104.bc.googleusercontent.com
- IP address: 104.196.255.44
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Cogent Biosciences"
About – Cogent Biosciences
Throughout his career in biotech he has managed the strategic build out of numerous finance teams aligning people, processes and systems to the strategic goals of the organization. This has included transactional support, strategic …See details»
Characterization of a Novel, EGFR Sparing, ErbB2 Inhibitor with ...
Apr 9, 2024 Characterization of a Novel, EGFR Sparing, ErbB2 Inhibitor with Activity Across Activating Mutations in Systemic and CNS Tumo rs. Jennifer Fulton, Tanna Bettendorf, …See details»
Cogent Biosciences - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +1 617 843 5032 Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to …See details»
Overview | Cogent Biosciences, Inc.
November 5, 2024 Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting Company to host webcast on …See details»
Cogent Biosciences - LinkedIn
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs.See details»
Cogent Biosciences Reports First Quarter 2024 Financial Results
May 7, 2024 The increase was primarily due to the growth of the organization. G&A expenses include non-cash stock compensation expense of $5.0 million for the first quarter of 2024 as …See details»
Press Release Details - Cogent Biosciences, Inc.
May 23, 2024 Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X …See details»
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial …
May 23, 2024 WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing …See details»
Research – Cogent Biosciences
2: [email protected]: March 2024 08:48 PM: [email protected]: March 2024 10:52 PM: Non-Advanced Systemic Mastocytosis: February 2024: Physician and Patient Perspectives on Relevant …See details»
Cogent Biosciences Reports Recent Business Highlights and …
Aug 6, 2024 The increase was primarily due to the growth of the organization. G&A expenses include non-cash stock compensation expense of $5.3 million for the second quarter of 2024 …See details»
Cogent Biosciences Announces Creation of Cogent Research Team
"Today marks an important step forward for Cogent Biosciences as we announce the formation of the Cogent Research Team with a focus on discovering and developing new small molecule …See details»
Privacy Policy – Cogent Biosciences
Oct 18, 2021 Email address: [email protected]. ... In some jurisdictions, we may be considered a “joint controller” with another organization, such as the study site where the Trial …See details»
Cogent Biosciences Reports Recent Business Highlights and First …
May 9, 2023 Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting Announced initiation of APEX Part 2 …See details»
Press Release Details - Cogent Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 5, 2020 /PRNewswire/ -- Unum Therapeutics Inc. ("Unum") (NASDAQ: UMRX), a biotechnology company focused on developing precision therapies for genetically …See details»
Careers – Cogent Biosciences
Cole is an accomplished executive with extensive commercial development, new product launch, P&L, and strategic leadership experience over a 20 plus year career in the pharmaceutical …See details»
Cogent Biosciences Provides Corporate Updates and Reports First …
May 12, 2021 Cogent Biosciences is based in Cambridge, MA and Boulder, Co. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: …See details»
Cogent Biosciences Provides Corporate Updates and Reports First …
May 12, 2021 "We are on track to initiate three clinical trials of CGT9486 this year, beginning with a study in Advanced Systemic Mastocytosis (AdvSM) patients for which we recently …See details»
Pipelines & Targets – Cogent Biosciences
Cole is an accomplished executive with extensive commercial development, new product launch, P&L, and strategic leadership experience over a 20 plus year career in the pharmaceutical …See details»
Cogent Biosciences Provides 2022 Corporate Guidance
Jan 5, 2022 CAMBRIDGE, Mass. and BOULDER, Colo., Jan. 5, 2022 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision …See details»